Initiative to drive the adoption of health innovation which enables long-term prevention of stroke, heart attacks and other serious cardiovascular events.
By 2050, one in four people in Asia and the Pacific will be over 60 years old. An increase in age is inevitably accompanied by a concurrent increase in chronic medical conditions like cardiovascular diseases (CVDs).
As the cause of more than 17 million deaths annually, with Asia accounting for about half of them, CVD is the world’s largest noncommunicable disease (NCD) by morbidity and mortality. This burden is projected to rise with the region’s ageing population.
Bayer in partnership with NUS Enterprise, the entrepreneurial arm of the National University of Singapore (NUS) announced a new initiative to drive adoption of health innovation in CVD prevention in seniors in the Asia-Pacific region.
The initiative – Healthy Hearts, Healthy Aging, comprises of a forum, report, among other initiatives, aims to bring healthcare experts, policy makers, innovators, academia, non-governmental organizations (NGOs) and corporations together to examine the role of health innovations in preventing serious cardiovascular (CV) events such as strokes and heart attacks in seniors living with CVD.
Bayer will draw on NUS Enterprise’s expertise and experience in engaging the regional startup ecosystem for innovation to develop a report which gathers research data and critical insights from multi-disciplinary teams of experts across the region.
The report will examine the CV health imperatives associated with ageing populations across the Asia-Pacific.
The report will also gather recommendations on how different stakeholders can collaborate to enhance the adoption of health innovation in the long-term preventive care of CVD patients. It is planned for a June 2019 completion. [APBN]